A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : HER2

Search Conditions:
Search Keyword : HER2
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: HER2
Appearance Frequency: 4740 time(s)
Long forms: 106

Display Settings:
[Display Entries]
Long Form, 100 entries
    (Appearance freq, Descending)
Long Form, all entries
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
human epidermal growth factor receptor 2
(4470 times)
Neoplasms
(2359 times)
ER (950 times)
PR (661 times)
IHC (392 times)
1998 Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.
HER2/neu
(57 times)
Neoplasms
(36 times)
ER (11 times)
PR (9 times)
FISH (7 times)
1995 Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.
human epidermal receptor 2
(43 times)
Neoplasms
(28 times)
EGFR (8 times)
ER (6 times)
OS (6 times)
2003 [Association between the survival time and high-expression of EGFR and HER-2 in breast cancer].
human EGFR2
(19 times)
Neoplasms
(8 times)
EGFR (15 times)
5-FU (1 time)
ADC (1 time)
2005 Role of iron in inactivation of epidermal growth factor receptor after asbestos treatment of human lung and pleural target cells.
human EGF receptor 2
(17 times)
Neoplasms
(6 times)
EGFR (3 times)
UMOD (2 times)
ACE (1 time)
2003 Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases.
human growth factor receptor-2
(9 times)
Neoplasms
(2 times)
AE (1 time)
DLT (1 time)
EGFR (1 time)
2006 HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
human ErbB2
(4 times)
Neoplasms
(3 times)
APC (2 times)
EGFR (1 time)
IL (1 time)
2005 Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
Her-2/neu protein
(3 times)
Neoplasms
(2 times)
ER (1 time)
FISH (1 time)
mHag (1 time)
2009 The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag).
HER2-binding Z
(3 times)
Nuclear Medicine
(2 times)
PET (1 time)
2008 [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.
10  HER2/neu receptor
(3 times)
General Surgery
(2 times)
HR (3 times)
CIs (1 time)
ER (1 time)
2011 Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
11  hormone receptor 2
(3 times)
Neoplasms
(3 times)
ER (2 times)
CNB (1 time)
DFS (1 time)
2012 Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
12  anti-HER2 Affibody molecule Z
(2 times)
Biochemistry
(1 time)
MMA-NOTA (1 time)
2011 Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
13  anti-HER2 Z
(2 times)
Nuclear Medicine
(2 times)
CD (1 time)
ESI-MS (1 time)
maEES (1 time)
2008 Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
14  hEGF receptor-2
(2 times)
Neoplasms
(2 times)
--- 2012 Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
15  HER2 amplification
(2 times)
Pathology
(1 time)
ER (1 time)
FISH (1 time)
PR (1 time)
2010 Triple-negative breast cancers: unique clinical presentations and outcomes.
16  HER2 and its Z
(2 times)
Nanomedicine
(1 time)
SPRi (1 time)
2015 Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.
17  HER2 over-expression
(2 times)
Radiology
(1 time)
BLBC (1 time)
DM (1 time)
ER/PR (1 time)
2016 Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype.
18  HER2 protein
(2 times)
Pathology
(1 time)
HER2 ECD (1 time)
1996 Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu.
19  HER2-binding affibody molecule Z
(2 times)
Nuclear Medicine
(2 times)
--- 2012 HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
20  HER2-ECD
(2 times)
Neoplasms
(1 time)
ER (1 time)
2014 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
21  HER2-positive
(2 times)
Neoplasms
(2 times)
BCS (1 time)
DFS (1 time)
ENI (1 time)
2012 Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
22  HER2/neu/c-erbB2
(2 times)
Molecular Biology
(1 time)
APCs (1 time)
CHM (1 time)
CHP (1 time)
1994 Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides.
23  high expression of epidermal growth factor receptor 2
(2 times)
Neoplasms
(2 times)
ALDH1A1 (1 time)
CSC (1 time)
ER (1 time)
2014 ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis.
24  human c-ErbB2
(2 times)
Neoplasms
(1 time)
BC (1 time)
BCs (1 time)
2016 Clinical applications of mouse models for breast cancer engaging HER2/neu.
25  human EGFR type 2 receptor
(2 times)
Neoplasms
(2 times)
EGFR (2 times)
TKIs (2 times)
ATP (1 time)
2013 Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
26  anti-HER2 Affibody Z
(1 time)
Nuclear Medicine
(1 time)
PIB (1 time)
2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
27  anti-HER2 Affibody-PNA chimera, Z
(1 time)
Biochemistry
(1 time)
CD (1 time)
PNA (1 time)
SPR (1 time)
2015 Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
28  anti-human EGFR type 2
(1 time)
Drug Therapy
(1 time)
EGFR (1 time)
VEGF (1 time)
2007 EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
29  Anti-Human Epithelial Receptor Type 2
(1 time)
Neoplasms
(1 time)
GBM (1 time)
2007 Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.
30  had an ERBB2
(1 time)
Neoplasms
(1 time)
AC (1 time)
HBC (1 time)
2007 A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
31  had concurrent Erb-b2 receptor tyrosine kinase 2 gene
(1 time)
Neoplasms
(1 time)
CGP (1 time)
TMD (1 time)
2017 HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
32  had the same level of tumour accumulation as (125)I-PIB-Z
(1 time)
Nuclear Medicine
(1 time)
HPEM (1 time)
2009 Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.
33  harboured similar gains, losses, amplifications of 9p23 and 17q12
(1 time)
Pathology
(1 time)
HUMARA (1 time)
2010 Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas.
34  have frequently been linked to ERBB2
(1 time)
Molecular Biology
(1 time)
FISH (1 time)
2010 Aberrations of ERBB2 and TOP2A genes in breast cancer.
35  HBEGF, ERBB2
(1 time)
Neoplasms
(1 time)
AREG (1 time)
BTC (1 time)
EPGN (1 time)
2015 Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
36  HER-2/neu oncogene
(1 time)
Pathology
(1 time)
topo IIalpha (1 time)
2006 Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
37  HER2 Affibody analogue, Ac-Cys-Z
(1 time)
Biochemistry
(1 time)
HSA (1 time)
PET (1 time)
SPECT (1 time)
2011 Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.
38  HER2 and chromosome-17, as well for p185
(1 time)
Neoplasms
(1 time)
FISH (1 time)
2007 Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues.
39  HER2 FISH-ambiguous
(1 time)
General Surgery
(1 time)
FISH (1 time)
IHC (1 time)
2013 Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
40  HER2 NT
(1 time)
Natural Science Disciplines
(1 time)
PDA (1 time)
2018 Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.
41  HER2 oncogene or p185
(1 time)
Neoplasms
(1 time)
PDAC (1 time)
2004 Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma.
42  HER2 overexpressors. p185
(1 time)
Science
(1 time)
FAS (1 time)
RNAi (1 time)
2004 Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
43  HER2 PET
(1 time)
Nuclear Medicine
(1 time)
--- 2008 Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.
44  HER2 receptor and Z
(1 time)
Allergy and Immunology
(1 time)
--- 2008 Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
45  HER2 receptor more strongly, compared to Z
(1 time)
Biotechnology
(1 time)
--- 2014 Affinity enhancement of HER2-binding Z(HER2:342) affibody via rational design approach: a molecular dynamics study.
46  HER2 receptor protein
(1 time)
General Surgery
(1 time)
DFS (1 time)
EGFR (1 time)
Ki-67 (1 time)
2003 Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
47  HER2 targeting specificity, Z
(1 time)
Biochemistry
(1 time)
BNCs (1 time)
2010 Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells.
48  HER2+ with complete (100%) concordance with ERBB2
(1 time)
Neoplasms
(1 time)
CRGA (1 time)
GA (1 time)
IBC (1 time)
2015 Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
49  HER2-aro
(1 time)
Neoplasms
(1 time)
AI (1 time)
ER (1 time)
2012 AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
50  HER2-binding surface of Z
(1 time)
Molecular Biology
(1 time)
PCA (1 time)
2011 Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
51  Her2-coded p185
(1 time)
Neoplasms
(1 time)
ECD (1 time)
MUFA (1 time)
OA (1 time)
2006 Mediterranean diet, olive oil and cancer.
52  HER2-DIVMP
(1 time)
Chemistry
(1 time)
--- 2013 Fluorescence study for selecting specific ligands toward HER2 receptor: an example of receptor fragment approach.
53  HER2-expressing cells of ((111)In-MMA-NODAGA-Cys(61))-Z
(1 time)
Biology
(1 time)
MMA-NODAGA (1 time)
2012 Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA.
54  HER2-expressing xenografts than the use of 125I-DABI-Z
(1 time)
Genetics, Medical
(1 time)
PIB (1 time)
2007 Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand.
55  HER2-expressing xenografts using 111In-benzyl-DOTA-Z
(1 time)
Genetics, Medical
(1 time)
p.i (1 time)
2007 Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
56  HER2-expressing xenografts using radioiodinated Z
(1 time)
Nuclear Medicine
(1 time)
--- 2007 Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
57  HER2-expressing xenografts using Z
(1 time)
Nuclear Medicine
(1 time)
--- 2007 Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
58  HER2-mab
(1 time)
Neoplasms
(1 time)
FISH (1 time)
GA (1 time)
GCN (1 time)
2012 p95HER2 truncated form in resected non-small cell lung cancer.
59  her2-neu
(1 time)
Neoplasms
(1 time)
CI (1 time)
HR (1 time)
HzR (1 time)
2018 Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
60  HER2-overexpressed xenografts (SKOV-3) by (186)Re-maGSG-Z
(1 time)
Nuclear Medicine
(1 time)
maGGG (1 time)
maGSG (1 time)
2010 (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
61  HER2-overexpressing breast tumours co-expresses p95
(1 time)
Pathology
(1 time)
--- 2013 Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.
62  HER2-positive metastatic breast carcinoma with a coexisting ERBB2
(1 time)
Neoplasms
(1 time)
TTF-1 (1 time)
2015 Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
63  HER2-positive, ER-negative, PR-negative
(1 time)
Neoplasms
(1 time)
DFS (1 time)
ER (1 time)
FAC (1 time)
2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
64  HER2-specific Affibody molecule Z
(1 time)
Nuclear Medicine
(1 time)
--- 2013 Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
65  HER2-specific Affibody tracer, (MMA-DOTA-Cys61)-Z
(1 time)
Molecular Biology
(1 time)
--- 2010 Design of an optimized scaffold for affibody molecules.
66  HER2-targeted therapy for breast and gastric patients with ERBB2
(1 time)
Neoplasms
(1 time)
--- 2018 Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
67  HER2-targeting agents Z
(1 time)
Nuclear Medicine
(1 time)
--- 2008 Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules.
68  HER2/c-erbB-2
(1 time)
Pathology
(1 time)
dPCR (1 time)
FISH (1 time)
IHC (1 time)
2003 Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
69  her2/neu gene
(1 time)
Antineoplastic Agents
(1 time)
--- 2012 A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers.
70  HER2/neu gene encodes a 185 kDa transmembrane receptor
(1 time)
Drug Therapy
(1 time)
--- 1999 Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.
71  HER2CA
(1 time)
Natural Science Disciplines
(1 time)
ARE (1 time)
DN-NRF2 (1 time)
2014 HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction.
72  heterodimer with other ErbB family members, such as ErbB2
(1 time)
Molecular Biology
(1 time)
EGF (1 time)
EGFR (1 time)
HRGbeta1 (1 time)
2012 Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
73  Heterodimers of the ligand-binding-deficient ERBB2
(1 time)
Science
(1 time)
ECD (1 time)
2012 Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling.
74  heterogeneous ERBB2
(1 time)
Molecular Biology
(1 time)
FISH (1 time)
qPCR (1 time)
2013 Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma.
75  high ERBB2
(1 time)
Neoplasms
(1 time)
HER2Mab (1 time)
2012 ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
76  high frequency of activating extracellular domain ERBB2
(1 time)
Neoplasms
(1 time)
MPUC (1 time)
NGS (1 time)
non-MPUC (1 time)
2014 A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
77  high levels of erbB2
(1 time)
Neoplasms
(1 time)
--- 2016 Targeting peptidyl-prolyl isomerase pin1 to inhibit tumor cell aggressiveness.
78  high melting temperature (T(m)), both in HP1:HP2 and in Z
(1 time)
Biochemistry
(1 time)
CD (1 time)
PNA (1 time)
SPR (1 time)
2015 Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.
79  higher for (124)I-PIB-Z
(1 time)
Nuclear Medicine
(1 time)
PIB (1 time)
2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
80  higher rates in patients with epidermal growth factor receptor 2
(1 time)
Neoplasms
(1 time)
BC (1 time)
BMs (1 time)
MBC (1 time)
2015 Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases.
81  higher sensitivity to predict ERBB2
(1 time)
Neoplasms
(1 time)
DFS (1 time)
ECD (1 time)
QIF (1 time)
2015 Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
82  higher than that of (124)I-PIB-Z
(1 time)
Nuclear Medicine
(1 time)
PIB (1 time)
2009 On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
83  highly significant positive correlation of icb-1 transcript levels with c-erbB2
(1 time)
Neoplasms
(1 time)
--- 2010 Icb-1 Gene expression is elevated in human endometrial adenocarcinoma and is closely associated with HER2 expression.
84  histologic subtypes and frequent amplification and overexpression of ERBB2
(1 time)
Pathology
(1 time)
--- 2015 Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2).
85  histology, and epidermal growth factor receptor 2
(1 time)
General Surgery
(1 time)
DFS (1 time)
FISH (1 time)
IHC (1 time)
2015 The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer.
86  homodimer of the c-erbB2
(1 time)
Neoplasms
(1 time)
EMT (1 time)
2014 Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition.
87  homolog c-erbB-2
(1 time)
General Surgery
(1 time)
--- 2003 Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer.
88  hormone receptor-negative tumors, epidermal growth factor receptor 2
(1 time)
Complementary Therapies
(1 time)
--- 2013 High risk factors of brain metastases in 295 patients with advanced breast cancer.
89  hormone receptor-positive and ERBB2
(1 time)
Biochemistry
(1 time)
PrgR (1 time)
2008 The UPS: a promising target for breast cancer treatment.
90  HR-negative, HER2-positive
(1 time)
Antineoplastic Agents
(1 time)
CI (1 time)
HR (1 time)
pOR (1 time)
2016 Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.
91  human cancer cells overexpressing epidermal growth factor receptor 2
(1 time)
Biochemistry
(1 time)
DARPin (1 time)
GNPs (1 time)
2017 Synthesis, Characterization, and Selective Delivery of DARPin-Gold Nanoparticle Conjugates to Cancer Cells.
92  human EGFR type 2
(1 time)
Neoplasms
(1 time)
Eaff (1 time)
EGFR (1 time)
NIR (1 time)
2010 In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore.
93  human EGFR-related 2
(1 time)
Neoplasms
(1 time)
EGFR (1 time)
GISTs (1 time)
PDGFRA (1 time)
2010 Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment.
94  human EGFR2 gene
(1 time)
Neoplasms
(1 time)
EGFR (1 time)
NSCLC (1 time)
TKIs (1 time)
2018 Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
95  human epidemiological receptor 2
(1 time)
Neoplasms
(1 time)
CRP (1 time)
HR (1 time)
ORs (1 time)
2013 Preoperative serum C-reactive protein levels and early breast cancer by BMI and menopausal status.
96  human epidermal growth factor receptor tyrosine kinase 2
(1 time)
Neoplasms
(1 time)
--- 2005 Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
97  Human Epidermal Receptor Growth Factor 2
(1 time)
Medicine
(1 time)
ER (1 time)
2007 Tissue microarrays for testing basal biomarkers in familial breast cancer cases.
98  human NK-92 cells to the tumor-associated ErbB2
(1 time)
Molecular Biology
(1 time)
CARs (1 time)
NK (1 time)
2015 Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
99  human receptor tyrosine-protein kinase erbB-2
(1 time)
Proteome
(1 time)
FFPE (1 time)
2015 Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues.
100  human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2
(1 time)
Neoplasms
(1 time)
CI (1 time)
HR (1 time)
2015 Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.